97 related articles for article (PubMed ID: 15976508)
1. Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time.
Lu WX; Jones-Burton C; Zhan M; Salzberg DJ; Moore J; Fink JC
Nephron Clin Pract; 2005; 101(2):c79-86. PubMed ID: 15976508
[TBL] [Abstract][Full Text] [Related]
2. Use of erythropoietin before the initiation of dialysis and its impact on mortality.
Fink J; Blahut S; Reddy M; Light P
Am J Kidney Dis; 2001 Feb; 37(2):348-55. PubMed ID: 11157377
[TBL] [Abstract][Full Text] [Related]
3. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States.
Stack AG
Am J Kidney Dis; 2003 Feb; 41(2):310-8. PubMed ID: 12552491
[TBL] [Abstract][Full Text] [Related]
4. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval.
Powe NR; Griffiths RI; de Lissovoy G; Anderson GF; Watson AJ; Greer JW; Herbert RJ; Eggers PW; Milam RA; Whelton PK
JAMA; 1992 Sep; 268(11):1434-40. PubMed ID: 1512912
[TBL] [Abstract][Full Text] [Related]
5. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations.
Collins AJ
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 2():ii2-6. PubMed ID: 12819293
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic study of recombinant human erythropoietin treatment in pre-dialysis end stage renal disease patients.
Yamazaki C; Watanabe Y; Sakamoto N
Nihon Jinzo Gakkai Shi; 1993 Nov; 35(11):1233-42. PubMed ID: 8139135
[TBL] [Abstract][Full Text] [Related]
7. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states.
Thamer M; Richard C; Ray NF; Greer JW; Cotter DJ; Pearson BC
Am J Kidney Dis; 1996 Aug; 28(2):235-49. PubMed ID: 8768919
[TBL] [Abstract][Full Text] [Related]
8. Trends in anemia at initiation of dialysis in the United States.
Obrador GT; Roberts T; St Peter WL; Frazier E; Pereira BJ; Collins AJ
Kidney Int; 2001 Nov; 60(5):1875-84. PubMed ID: 11703606
[TBL] [Abstract][Full Text] [Related]
9. [Changes in the prognosis for survival of patients with end-stage renal disease (ESRD) treated by hemodialysis].
Sakurabayashi T; Kikuchi H; Nakayama H; Osawa Y; Shimada H; Miyazaki S; Yuasa Y; Sakai S; Suzuki M; Takahashi S; Hirasawa Y
Nihon Jinzo Gakkai Shi; 2008; 50(2):127-34. PubMed ID: 18421969
[TBL] [Abstract][Full Text] [Related]
10. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients.
Xue JL; St Peter WL; Ebben JP; Everson SE; Collins AJ
Am J Kidney Dis; 2002 Dec; 40(6):1153-61. PubMed ID: 12460033
[TBL] [Abstract][Full Text] [Related]
11. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
Nissenson AR
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
[TBL] [Abstract][Full Text] [Related]
12. Duration of end-stage renal disease and kidney transplant outcome.
Goldfarb-Rumyantzev A; Hurdle JF; Scandling J; Wang Z; Baird B; Barenbaum L; Cheung AK
Nephrol Dial Transplant; 2005 Jan; 20(1):167-75. PubMed ID: 15546892
[TBL] [Abstract][Full Text] [Related]
13. The effects of recombinant human erythropoietin on the cell mediated immune response of renal failure patients.
Singh AB; Singh M; Palekar S; Levy S; Nunn C; Mann RA
J Med; 1992; 23(5):289-302. PubMed ID: 1469332
[TBL] [Abstract][Full Text] [Related]
14. Significance of serum creatinine values in new end-stage renal disease patients.
Fink JC; Burdick RA; Kurth SJ; Blahut SA; Armistead NC; Turner MS; Shickle LM; Light PD
Am J Kidney Dis; 1999 Oct; 34(4):694-701. PubMed ID: 10516351
[TBL] [Abstract][Full Text] [Related]
15. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study).
Benz RL; Pressman MR; Hovick ET; Peterson DD
Am J Kidney Dis; 1999 Dec; 34(6):1089-95. PubMed ID: 10585319
[TBL] [Abstract][Full Text] [Related]
16. [Reticulocyte response after immediate withdrawal of recombinant human erythropoietin in chronic hemodialysis patients].
Caramelo C; Soto C; Neira F; López MD; Jiménez S; Albalate M; de Oña R; Llamas P; Deudero JJ
Nefrologia; 2004; 24(4):351-6. PubMed ID: 15455495
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of anemia in patients with chronic renal insufficiency undergoing hemodialysis with recombinant human erythropoietin: 12 months' experience].
de Sousa FT; Prata MM; Barbas JV; dos Santos JP
Acta Med Port; 1990; 3(6):347-52. PubMed ID: 2089856
[TBL] [Abstract][Full Text] [Related]
18. Intravenous iron attenuates postvaccination anti-HBsAg titres after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy.
Liu JH; Liu YL; Lin HH; Yang YF; Kuo HL; Lin PW; Huang CC
Int J Clin Pract; 2009 Mar; 63(3):387-93. PubMed ID: 18410348
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human erythropoietin in a patient with multiple myeloma and end-stage renal disease.
Holley JL; Nolan TA; Piraino B
Clin Nephrol; 1992 Mar; 37(3):145-7. PubMed ID: 1563119
[TBL] [Abstract][Full Text] [Related]
20. Survival among patients with kidney failure in Jalisco, Mexico.
Garcia-Garcia G; Briseño-Rentería G; Luquín-Arellan VH; Gao Z; Gill J; Tonelli M
J Am Soc Nephrol; 2007 Jun; 18(6):1922-7. PubMed ID: 17494884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
